Filing Flows

Filing Flows › Companies › ProPhase Labs › Cash flow

ProPhase Labs cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$78K in Q2 2026 · −$5.5M over twelve months

Operating cash flow−$78K
Free cash flow−$78K

Analysis

In Q2 2026, ProPhase Labs generated −$78K of operating cash flow. That is $169K more than in Q2 2025 (−$247K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$5.5M; the largest uses were operating cash flow ($5.5M); besides operations, cash came from other financing ($3.4M), net borrowing (+) / repaid (−) ($2.0M); the cash balance fell by $149K.

Operating cash flow was −$78K against net income of −$3.1M. The largest differences: payables +$1.2M, depreciation & amortization +$963K, stock-based pay +$375K.

Free cash flow

ProPhase Labs: free cash flow by quarterProPhase Labs: free cash flow by quarter−$4.0MQ3 2024−$3.6MQ4 2024−$3.4MQ1 2025−$247KQ2 2025−$3.5MQ3 2025−$1.2MQ4 2025−$748KQ1 2026−$78KQ2 2026
Operating cash flow less capital spending.
ProPhase Labs: operating cash flow against capital spendingProPhase Labs: operating cash flow against capital spendingOperating cash flowCapital spending−$4.0M−$1KQ3 2024−$3.5M$40KQ4 2024−$3.4M$0Q1 2025−$247K$0Q2 2025−$3.5M$0Q3 2025−$1.2M$0Q4 2025−$748K$0Q1 2026−$78K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$78K, Capital spending $0.

Capital allocation, year by year

ProPhase Labs: where the cash came from (up) and went (down), by fiscal yearProPhase Labs: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksDividendsFY2021: Operating cash flow −$13.6MFY2021: Net borrowing −$45KFY2021: Shares issued $35.1MFY2021: Capital spending −$4.2MFY2021: Acquisitions −$9.1MFY2021: Buybacks −$917KFY2021: Dividends −$4.5M$35.1MFY2021FY2022: Operating cash flow $28.6MFY2022: Net borrowing −$7.0MFY2022: Asset sales $452KFY2022: Capital spending −$3.9MFY2022: Buybacks −$2.2MFY2022: Dividends −$9.4M$29.0MFY2022FY2023: Operating cash flow −$11.9MFY2023: Net borrowing $7.6MFY2023: Asset sales $46KFY2023: Capital spending −$2.1MFY2023: Acquisitions −$2.9MFY2023: Buybacks −$588K$7.6MFY2023FY2024: Operating cash flow −$17.5MFY2024: Asset sales $229KFY2024: Capital spending −$906K$229KFY2024FY2025: Operating cash flow −$8.3MFY2025: Net borrowing $3.0MFY2025: Shares issued $3.6MFY2025: Asset sales $120K$6.7MFY2025
Over these 5 years operating cash flow totalled −$22.8M; the largest uses were operating cash flow ($51.4M) and dividends ($13.9M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$20K
Debtnone
Net cash$20K
Cash runway0 months

ProPhase Labs is burning cash: its operations consume cash, a free cash flow of −$5.5M a year at the current rate against $20K of cash and investments: a runway of about 0 months before any new financing.

Where the cash came from and went

ProPhase Labs: sources (+) and uses (−) of cash, Q2 2026ProPhase Labs: sources (+) and uses (−) of cash, Q2 2026Other financing$205KNet borrowing (+) / repaid (−)−$138KOperating cash flow−$78KCash drawn (+) / kept (−)$11K
ProPhase Labs: sources (+) and uses (−) of cash, TTM to Q2 2026ProPhase Labs: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$5.5MOther financing$3.4MNet borrowing (+) / repaid (−)$2.0MCash drawn (+) / kept (−)$149KShares issued$41KAsset & business sales$12K

From profit to cash

ProPhase Labs: net income to operating cash flow, Q2 2026ProPhase Labs: net income to operating cash flow, Q2 2026Net income−$3.1MDepreciation & amortization$963KStock-based pay$375KPayables$1.2MDeferred revenue−$15KPrepaid and other assets$37KOther liabilities−$11KIncome taxes payable−$2KOperating cash flow−$78K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202514701752515-870
Q1 20251266114134535
Q4 20241592143816918
Q3 2024209830011141284

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$78K—−$138K—$11K−$78K
Q1 2026−$748K—$348K$41K$59K−$748K
Q4 2025−$1.2M———$315K−$1.2M
Q3 2025−$3.5M—$722K—−$236K−$3.5M
Q2 2025−$247K—−$519K$280K−$81K−$247K
Q1 2025−$3.4M—−$1.3M$3.3M$590K−$3.4M
Q4 2024−$3.5M−$40K−$1.8M−$4.6M−$177K−$3.6M
Q3 2024−$4.0M$1K$2.9M—$1.3M−$4.0M

ProPhase Labs: income statement and cash flow

ProPhase Labs, Q2 2026: revenue $1.0M (-19% year over year), operating margin -261.6%. The chart follows the revenue to costs, profit and cash.

ProPhase Labs: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.